

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”) is pleased to announce that Mr. CHEONG Shin Keong (鄭善強) (“**Mr. Cheong**”) has been appointed as a non-executive director of the Company with effect from 24 March 2020.

The biographical details of Mr. Cheong are set out below:

Mr. Cheong, aged 63, is an independent non-executive director of Bossini International Holdings Limited (stock code: 592), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) since September 2017, and from January 2015 to January 2020 was an executive director of Television Broadcasts Limited (stock code: 511), a company listed on the Main Board of the Stock Exchange. Mr. Cheong joined Television Broadcasts Limited as Controller, Marketing & Sales in March 1989 and assumed the duties of General Manager in April 2004. Mr. Cheong has extensive experience in the advertising and marketing industry and contributes actively to the professional development of marketing in Hong Kong through leading marketing industry bodies. He is a Fellow and a Vice-Chairman of the Hong Kong Management Association as well as a Fellow and Hong Kong Regional Board President of the Chartered Institute of Marketing.

The Company has entered into a letter of appointment with Mr. Cheong in relation to his appointment as a non-executive director of the Company. He has been appointed for a term of three years, with effect from 24 March 2020. Mr. Cheong will hold the office until the forthcoming annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. He is entitled to a director’s fee of HK\$100,000 per quarter, which has been recommended by the remuneration committee of the Board and approved by the Board, having considered his responsibilities and job duties, the Company’s remuneration policy and the prevailing market conditions.

Save as disclosed above and as far as the directors of the Company are aware, Mr. Cheong does not (i) hold any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); (ii) have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; (iii) hold any other position in the Group; or (iv) hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above and so far as the directors of the Company are aware, there is no other matter relating to the appointment of Mr. Cheong that needs to be brought to the attention of the shareholders of the Company and there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Company would like to welcome Mr. Cheong in joining the Board.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 24 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie and Ms. Man Yee Wai, Viola; the non-executive directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.